Khloris Biosciences, Inc.

5729 Fontanoso Way
San Jose
United States


Show jobs for this employer

About Khloris Biosciences, Inc.

Pioneering Cancer Vaccination Defining the Future of Cancer and Cardiovascular Medicine

Khloris is the first and only company to develop an iPSC-derived whole cell vaccine for the treatment of cancer. Fundamentally differentiated from previous cancer vaccinations, iPSC vaccination combines key mechanistic elements to boost anti-tumor immunity. Presenting a broad spectrum of oncofetal and other cancer-related antigens, iPSC vaccination fully mobilizes the immune system.

Khloris is also developing iPSC-derived cardiomyocytes as a novel cell therapy treatment for patients with cardiovascular diseases. 

1 article with Khloris Biosciences, Inc.